Cargando…
Metastatic melanoma and vemurafenib: novel approaches
Metastatic melanoma (MM) presents a treatment challenge to oncologists worldwide. Dacarbazine is the first line chemotherapy treatment for MM, though the overall response rates are very poor. Recently, the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation was found to play a main r...
Autor principal: | De Mello, Ramon Andrade |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401159/ https://www.ncbi.nlm.nih.gov/pubmed/22826788 http://dx.doi.org/10.4081/rt.2012.e31 |
Ejemplares similares
-
Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
por: Castellani, Elisa, et al.
Publicado: (2012) -
Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
por: de Haan, Jorine, et al.
Publicado: (2018) -
T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014) -
Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
por: Wolf, Sanne EJ, et al.
Publicado: (2013) -
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)